CRDF · Cardiff Oncology, Inc.

Cardiff Oncology, Inc. formalized the exits of CEO Dr. Mark Erlander and CFO James Levine through separation agreements on March 27, 2026, following their January 26, 2026, step-downs amid a strategic review. This signals a leadership transition phase, with significant severance commitments totaling over $1.1 million in base salary continuation alone, plus bonuses, healthcare, and equity treatment. Erlander's package includes unique elements like a consulting role and extended option vesting to June 2026, potentially retaining his expertise short-term while ensuring a clean break. Levine's terms mirror standard severance with option exercisability extended 12 months. Erlander's director resignation completes his board separation. These arrangements, including releases and confidentiality, mitigate litigation risk but represent a cash outflow impacting the biotech firm's runway. Investors should note the absence of new leadership appointments in this filing, highlighting ongoing uncertainty in executive stability critical for clinical-stage operations.